Dor BioPharma has received a European patent for its Lipid Polymer Micelle (LPM) technology, for the improved oral delivery of drugs. The issued European patent, EP 1460992, entitled
Watson Laboratories, a subsidiary of Watson’s, has received approval from the FDA to market its over-the-counter Nicotine Polacrilex Gum USP, 2mg and 4mg strengths, in the coated fruit
Wyeth and Takeda have received approval from the Japanese Ministry of Health, Labour and Welfare, to add the indication of treating polyarticular Juvenile Idiopathic Arthritis (JIA) to Enbrel
AlphaRx has reported positive preclinical results on GAI-122 injectable nano-emulsion in multiple models of acute hepatitis. GAI-122 reduced Aminotransferase (ALT) following IP administration in three different preclinical models
FDA has accepted for review, Eisai’ supplemental new drug application (sNDA) for an alternative five-day dosing regimen for Dacogen (decitabine for injection). It is intended to treat patients
Salvat and WraSer Pharmaceuticals have entered into an exclusive license agreement to market Salvat’s Cetraxal in the US, for a period of ten years. The company said that
Biogen Idec has reported that FDA has granted PEGylated interferon beta-1a (BIIB017) Fast Track designation, for relapsing multiple sclerosis (RMS). Biogen Idec plans to enroll more than 1,200
Array has reported top-line results from its phase-I seven-day dose escalation trial up to 1200mg daily of p38 inhibitor, ARRY-797, in healthy volunteers. The top-line results were announced
Alnylam shall contribute more than 1500 issued or pending patents on its RNA interference (RNAi) technology patent estate, to the patent pool established by GlaxoSmithKline (GSK). Alnylam to
Transdel has completed the enrollment of patients in pivotal phase-III clinical study for Ketotransdel, a topical cream-based non-steroidal anti-inflammatory drug (NSAID) for acute pain. Moreover, the company expects
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.